MEDICAL POLICY STATEMENT	
Marketplace	
Policy Name & Number	Date Effective
Hyperthermic Intraperitoneal Chemotherapy-MP-MM-1338	01/01/2024
Policy Type	
MEDICAL	

Medical Policy Statement prepared by CareSource and its affiliates are derived from literature based on and supported by clinical guidelines, nationally recognized utilization and technology assessment guidelines, other medical management industry standards, and published MCO clinical policy guidelines. Medically necessary services include, but are not limited to, those health care services or supplies that are proper and necessary for the diagnosis or treatment of disease, illness, or injury and without which the patient can be expected to suffer prolonged, increased or new morbidity, impairment of function, dysfunction of a body organ or part, or significant pain and discomfort. These services meet the standards of good medical practice in the local area, are the lowest cost alternative, and are not provided mainly for the convenience of the member or provider. Medically

Hyperthermic Intraperitoneal Chemotherapy-MP-MM-1338 Effective Date: 01/01/2024

The MEDICAL Policy Stateme



Cancer. 2020;127:76-95. doi:10.1016/j.ejca.2019.10.034

- Ben Aziz M, Di Napoli R. Hyperthermic intraperitoneal chemotherapy. *StatPearls*. StatPearls Publishing; 2023. Accessed September 25, 2023. www.ncbi.nlm.nih.gov
- 5. Ceelen W, Demuytere J, de Hingh I. Hyperthermic intraperitoneal chemotherapy: a critical review. *Cancers*. 2021;13(13):3114. doi:10.3390/cancers13133114
- Chicago Consensus Working Group. The Chicago Consensus on peritoneal surface malignancies: management of appendiceal neoplasms. *Ann Surg Oncol.* 2020;27:1753-1760. doi:10.1245/s10434-020-08316-w
- Chicago Consensus Working Group. The Chicago Consensus on peritoneal surface malignancies: management of peritoneal mesothelioma. *Ann Surg Oncol.* 2020;27:1774-1779. doi:10.1245/s10434-020-08324-w
- Chicago Consensus Working Group. The Chicago Consensus on peritoneal surface malignancies: management of colorectal metastases. *Ann Surg Oncol.* 2020;27:1761-1767. doi:10.1245/s10434-020-08315-x
- Chicago Consensus Working Group. The Chicago Consensus on peritoneal surface malignancies: management of ovarian neoplasms. *Cancer*. 2020;126:2553-2560. doi:10.1002/cncr.32867
- 10. Cytoreductive surgery and HIPEC offers effective treatment for selected patients with peritopedi2c6c00111123878860789c(3p[(3thd) 10)25(0.05d0[.66c(pteT)=16c(i125)73251]12387866 (8))(002TIc).0787



Index is a strong predictor of incomplete cytoreductive surgery in ovarian cancer. *Ann Surg Oncol.* 2021;28(1):244-251. doi:10.1245/s10434-020-08649-6

 Lewis AL, Dabo-Trubelja A. Anesthesia for cytoreductive surgery with heated intraperitoneal chemotherapy. UpToDate. Updated August 23, 2023. Accessed September 25, 2023. www.uptodate.com

The MEDICAL Policy Statement detailed above has received due consideration as defined in the MEDICAL Policy Statement Policy and is approved.